![Page 1: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/1.jpg)
Atrial Fibrillation
E. Kevin Heist, MD, PhD
Updates in General Internal Medicine for Specialists January 28, 2019
![Page 2: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/2.jpg)
Disclosures
• Abbott – Consultant, Research Grant
• Biotronik – Consultant
• Boston Scientific – Consultant
• Medtronic – Consultant
• Pfizer – Consultant
![Page 3: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/3.jpg)
Outline
• AF Mechanisms
• Rate vs. Rhythm Control
• Methods of Rhythm Control – Pharmacologic – Ablation
• Stroke Prevention
– Pharmacologic – Devices
![Page 4: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/4.jpg)
![Page 5: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/5.jpg)
January et al, JACC 2014
Atrial Fibrillation Mechanisms and Causes
![Page 6: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/6.jpg)
Progression from Paroxysmal to Persistent AF
ScienceMedia.com
![Page 7: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/7.jpg)
Drug Therapy for Rate Control in AF
• Beta Blocker Therapy
• Calcium-Channel Blocker Therapy (Diltiazem, Verapamil)
• Digoxin (increased mortality in some studies)
• Amiodarone (useful in acutely ill patients, chronic use limited by drug toxicity)
![Page 8: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/8.jpg)
Digoxin Use and Overall Mortality
Vamos et al, EHJ 2015;36:1831-8
![Page 9: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/9.jpg)
Digoxin Use and Overall Mortality
Vamos et al, EHJ 2015;36:1831-8
AF
![Page 10: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/10.jpg)
Digoxin Use and Overall Mortality
Vamos et al, EHJ 2015;36:1831-8
AF
CHF
![Page 11: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/11.jpg)
RACE II: Intensity of Rate Control
Lenient: resting hr < 110 (rest 93 + 9 bpm achieved) Strict: resting hr < 80 hr mod exercise < 110 (rest 76 + 12 bpm achieved) Primary Outcome: -cardiovascular death -CHF hospitalization -stroke -systemic embolism -bleeding -life threatening arrhythmia
Van Gelder et al, NEJM 2010;362:1363-73
p=ns
![Page 12: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/12.jpg)
Electrical Cardioversion is effective, but…
…Atrial fibrillation often recurs
![Page 13: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/13.jpg)
Medical Rate vs. Rhythm Control: AFFIRM
Wyse et al, NEJM 2002;347:1825-33
![Page 14: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/14.jpg)
Observational Mortality Study of Rate vs. Rhythm Control in 26,130 Canadian Patients (66+ years old)
Ionescu-Ittu et al, Arc Int Med 2012;172:997-1004
![Page 15: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/15.jpg)
Drug Therapy: No Magic Pill…
![Page 16: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/16.jpg)
Rhythm Control: Amiodarone vs. Sotalol vs. Placebo
Singh, BN et al, NEJM 2005;352:1861-72
![Page 17: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/17.jpg)
January et al, JACC 2014
Antiarrhythmic Drug Therapy for AF
![Page 18: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/18.jpg)
Drug Therapy for AF Summary
• Hard endpoints with AF rate control are as good as rhythm control (anti-arrhythmic drugs)
• Beta blockers and calcium channel blockers are good rate control choices, digoxin may increase mortality
• Antiarrhythmic drugs for AF have moderate efficacy and potential for drug toxicity
![Page 19: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/19.jpg)
Ablation Procedures for Atrial Fibrillation
![Page 20: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/20.jpg)
Pulmonary Veins as Triggers of Paroxysmal Atrial Fibrillation
Haissaguerre et al, NEJM 1998;339:659
![Page 21: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/21.jpg)
Pulmonary Vein Isolation: Ablation for Paroxysmal AF
![Page 22: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/22.jpg)
Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF
*Protocol-Defined Treatment Failure: documented symptomatic atrial fibrillation
Wilber et al, JAMA 2010;303:333-40
![Page 23: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/23.jpg)
Cryothermy Ultrasound* Laser
Balloon Ablation Catheters
*investigational devices, not FDA approved
![Page 24: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/24.jpg)
AF Ablation Methods: Cryoballoon vs RA Ablation: “Fire and ICE”
Kuck et al, NEJM 2106;374:2234-45
![Page 25: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/25.jpg)
Lesion Sets in AF Ablation
January et al, JACC 2014
![Page 26: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/26.jpg)
Comparison of RF Ablation Approaches for Persistent AF: STAR-AF II
Verma et al, NEJM;2015:372:1812-22
![Page 27: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/27.jpg)
CABANA Study: AF ablation vs drug therapy
Packer et al, HRS Late Breaking Trials, May 2018
![Page 28: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/28.jpg)
CABANA Study: AF ablation vs drug therapy
Packer et al, HRS Late Breaking Trials, May 2018
![Page 29: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/29.jpg)
CABANA Study: AF ablation vs drug therapy
Packer et al, HRS Late Breaking Trials, May 2018
![Page 30: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/30.jpg)
AF and CHF
Is There Benefit to AF Ablation?
![Page 31: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/31.jpg)
Khan et al NEJM 2008;359:1778-85
PABA-CHF AF Ablation vs. AV Nodal Ablation/BiV Pacing
![Page 32: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/32.jpg)
CAMERA-MRI: AF Ablation vs Rate Control in CHF Patients (EF<45%)
Prabhu et al, JACC 2017;70:1949-61
![Page 33: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/33.jpg)
CASTLE-AF AF Ablation vs Medical Therapy in AF with CHF (EF<35%)
Marrouche et al, NEJM 2018;378:417-27
![Page 34: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/34.jpg)
CASTLE-AF AF Ablation vs Medical Therapy in AF with CHF (EF<35%)
Marrouche et al, NEJM 2018;378:417-27
![Page 35: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/35.jpg)
Surgical Approaches to AF
LA RA
Cannom AJC 2000;85:25D
![Page 36: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/36.jpg)
FAST Study: Catheter or Surgical Ablation for AF
Boersma et al, Circ 2012;125:23-30
Catheter Ablation: radiofrequency PVI (additional ablation lines at operator discretion) Surgical Ablation: VATS approach, radiofrequency PVI + LA ganglionated plexus ablation + LAA excision (additional ablation lines at operator discretion)
![Page 37: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/37.jpg)
FAST Study: Catheter or Surgical Ablation for AF
Boersma et al, Circ 2012;125:23-30
Catheter Ablation: radiofrequency PVI (additional ablation lines at operator discretion) Surgical Ablation: VATS approach, radiofrequency PVI + LA ganglionated plexus ablation + LAA excision (additional ablation lines at operator discretion)
![Page 38: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/38.jpg)
Conclusion Regarding AF Ablation
• AF catheter ablation is more effective than antiarrhythmic drugs, but is not a guarantee of no AF
• Tools and strategies for AF ablation are evolving
• AF ablation may particularly benefit CHF patients
• Surgical AF ablation (Maze) appears more effective and more risky than catheter AF ablation
![Page 39: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/39.jpg)
Stroke Prevention in Atrial Fibrillation
![Page 40: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/40.jpg)
Atrial Fibrillation and Warfarin Use
Larson, G, the Far Side
![Page 41: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/41.jpg)
Stroke Is One of the Most Common and Devastating Complications of AF
• All-cause stroke rate with AF is 5% per year
• AF - independent risk factor for stroke
– ~5-fold increase in stroke risk
– ~15% of all strokes caused by AF
– Stroke risk increases with age
• Stroke risk persists in asymptomatic AF
Fuster V, et al. Circulation. 2006;114:e257-e354. Wolf PA, et al. Stroke. 1991;22:983-988. Page RL, et al. Circulation. 2003;107:1141-1145. Hart RG, et al. J Am Coll Cardiol. 2000;35:183-187.
![Page 42: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/42.jpg)
January et al, JACC 2014;64:e1-76.
Stroke Risk Without Anticoagulation: CHADS2 and CHADS2-VASc
![Page 43: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/43.jpg)
Stroke Risk Without Anticoagulation: CHADS2-VASc
![Page 44: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/44.jpg)
Preadmission Medications for Patients With Known AF Admitted with Stroke
Gladstone D, et al. Stroke. 2009;40:235-240.
597 high risk AF patients admitted with stroke 2003–2007 in 12 stroke centers in Canada
29%
10%
29%
29%
2%
Warfarin/ therapeutic
Warfarin/sub- therapeutic
Single antiplatelet therapy
No Antithrombotics
Dual anti-platelet therapy
![Page 45: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/45.jpg)
ASSERT Study: stroke risk with pacemaker-detected atrial arrhythmias
• Atrial High Rate Episodes (AHRE) (> 6 min, > 190 bpm) found in 36% of pacemaker patients with no h/o AF
• AHRE increase risk of stroke/embolism by 2.5 fold – 0.69%/year (no AHRE)
– 1.61%/year (+ AHRE)
Healey et al, NEJM 2012;366:120-9
![Page 46: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/46.jpg)
CRYSTAL AF Study Detection of AF in cryptogenic stroke
• 441 patients age > 40 with cryptogenic stroke – No h/o AF and no AF on 24+ hour EKG monitor – Randomized to implantable cardiac monitor or usual care
Sanna et al, NEJM 2014;370:2478-86
![Page 47: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/47.jpg)
Anticoagulation and Antiplatelet Therapy
![Page 48: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/48.jpg)
Warfarin vs Placebo in Stroke Prevention in AF
100% 50% 0% -50% -100%
AFASAK-1
SPAF BAATAF
CAFA
SPINAF
EAFT ALL Trials
Favors Warfarin Favors Placebo/ Control
Hart R, et al. Ann Intern Med. 2007;146:857-867.
Warfarin reduces incidence of stroke by about 64%
![Page 49: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/49.jpg)
Aspirin vs Placebo in Stroke Prevention in AF
Favors Placebo/ Control
Antiplatelet therapy reduces incidence of stroke by about 22%
Hart R, et al. Ann Intern Med. 2007;146:857-867.
All Trials
100% 50% 0% -50% -100%
AFASAK-1 SPAF I EAFT ESPS-II LASAF, daily
UK-TIA, 300 mg daily
Favors Antiplatelet
LASAF, alternate day
UK-TIA, 1200 mg daily JAST Aspirin Trials SAFT ESPS II, Dipyridamole ESPS II, Combination
![Page 50: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/50.jpg)
Warfarin vs Antiplatelet Therapy in Stroke Prevention in AF
100% 50% 0% -50% -100% Favors Warfarin Favors Antiplatelet
Hart R, et al. Ann Intern Med. 2007;146:857-867.
AFASAK I AFASAK II
Chinese ATAFS EAFT PATAF
SPAF II, ≤ 75 yrs
SPAF II, >75 yrs
Aspirin trials
SIFA ACTIVE-W
NASPEAF
All Trials
![Page 51: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/51.jpg)
Primary outcome: stroke, systemic embolus, MI, vascular death. Connolly et al. Lancet. 2006;367:1903-1912.
ACTIVE* W: Cumulative Risk of Stroke
Years
RR = 1.72 (1.24–2.37), P = 0.001
Clopidogrel + aspirin
Oral anticoagulation therapy
Number at risk Clopidogrel 3335 3168 2419 941 + aspirin Oral anti- 3371 3232 2466 930 coagulation therapy
0 0
0.02
0.04
0.10
0.08
0.06 C
umul
ativ
e H
azar
d R
ates
0.5 1 1.5
![Page 52: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/52.jpg)
Importance of Time within Therapeutic Range Patients Treated at Centers with TTR Below or Above 65%
Connolly S, et al. Circulation. 2008;118:2029-2037.
C+A: clopidogrel plus aspirin; OAC: oral anticoagulation therapy RR: relative risk of stroke C+A vs OAC
![Page 53: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/53.jpg)
Hylek EM, et al. Ann Intern Med. 1994;120:897-902. Hylek EM, et al. N Engl J Med. 1996;335:540-546.
INR
Odds Ratio
0 5 6 8 1 2 3 4 7
5
15
10
1
Ischemic Stroke ICH Therapeutic
Window
Warfarin Has a Narrow Therapeutic Window
Relationship Between Clinical Events and INR Intensity in Patients with Atrial Fibrillation
![Page 54: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/54.jpg)
Atrial Fibrillation Patients – 55% of Their Time in Therapeutic INR Range
Baker W, et al. J Manag Care Pharm. 2009;15:244-252.
![Page 55: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/55.jpg)
Major Hemorrhage in First Year of Warfarin Therapy
Hylek EM, et al. Circulation. 2007;115:2689-2696.
0 100 200 300 Days on Warfarin
9 intracranial bleeds 3 fatal 8/9 age > 75
Age > 80 Age < 80
Prev
alen
ce o
f Maj
or H
emor
rhag
e
0.00
0.02
0.04
0.06
0.08
0.10
![Page 56: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/56.jpg)
An Ideal Anticoagulant
Sobieraj-Teague M, et al. Semin Thromb Hemost. 2009;35:515-524.
Desired Characteristic Practical Advantage
Rapid onset of action No need for overlap with heparin
Wide therapeutic index Increased safety
Minimal side effects Improved compliance; less monitoring
Oral formulation Convenient administration
Predictable anticoagulant response Fixed-dose unmonitored treatment
No food or drug interaction No need for monitoring
Availability of antidote Able to reverse in case of bleeding or urgent surgery
Cost effective Accessibility
![Page 57: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/57.jpg)
Emerging Therapies Factor Xa Inhibitors and Direct Thrombin Inhibitors
Harenberg J. Semin Thromb Hemost. 2009;35:574-586.
Tissue Factor/VIIa
IX
IXa
X
Xa
VIIIa
Va
II IIa
Fibrinogen Fibrin
Idrabiotaparinux
Rivaroxaban* Betrixaban Apixaban* YM150 Edoxaban*
Dabigatran* AZD-0837 *FDA Approved Drugs
![Page 58: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/58.jpg)
Apixaban – AVERROES
R N = 5,600
Atrial Fibrillation + 1 risk factor Failed or unsuitable for VKA therapy
Screening Phase 0-28 days
Apixaban 5 mg BID (Reduced to 2.5 mg/day for selected patients*)
ASA (81 to 324 mg/day)
*Patients with ≥ 2 of the following: •Age ≥ 80 yrs •Body weight ≤ 60 kg •Serum creatinine ≥ 1.5 mg/dL or 133 μmol/L
Primary efficacy outcome: stroke or systemic embolism Primary safety outcome: major bleeds Other outcomes: myocardial infarction, vascular death, all-cause death
Follow-up @ 1 and 3 months and every 3 months thereafter until study completion
NCT00496769. http://www.clinicaltrials.gov/ct2/show/NCT00496769. Accessed Sept 2010.
![Page 59: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/59.jpg)
Connolly S, et al. http://www.escardio.org/congresses/esc-2010/congress-reports/Pages/708-3-AVERROES.aspx. Accessed Sept 2010.
Apixaban – AVERROES Stroke or Systemic Embolic Event
Months
Cum
ulat
ive
Ris
k 0.05
0.03
0.01
0.0
0 3 6 9 12 18 21
Aspirin
RR = 0.46 95% CI = 0.33–0.64 P < 0.001
Apixaban
No. at Risk ASA 2791 2720 2541 2124 1541 626 329 Apix 2809 2761 2567 2127 1523 617 353
![Page 60: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/60.jpg)
Apixaban – AVERROES
Connolly S, et al. http://www.escardio.org/congresses/esc-2010/congress-reports/Pages/708-3-AVERROES.aspx. Accessed Sept 2010.
Outcome Apixaban (n = 2809)
Aspirin (n = 2791)
Relative Risk (95% CI) P value
Stroke or systemic embolic event 1.6 3.6 0.46 (0.33-0.64) < 0.001
Stroke, embolic event, MI, or vascular death
4.1 6.2 0.66 (0.53-0.83) < 0.001
Major bleeding 1.4 1.2 1.14 (0.74-1.75) 0.56
Fatal bleeding 0.1 0.1 0.84 (0.26-2.75) 0.77
Intracranial bleeding 0.4 0.3 1.09 (0.50-2.39) 0.83
![Page 61: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/61.jpg)
Apixaban – AVERROES
Connolly S, et al. http://www.escardio.org/congresses/esc-2010/congress-reports/Pages/708-3-AVERROES.aspx. Accessed Sept 2010.
Outcome Apixaban (n = 2809)
Aspirin (n = 2791)
Relative Risk (95% CI) P value
Stroke or systemic embolic event 1.6 3.6 0.46 (0.33-0.64) < 0.001
Stroke, embolic event, MI, or vascular death
4.1 6.2 0.66 (0.53-0.83) < 0.001
Major bleeding 1.4 1.2 1.14 (0.74-1.75) 0.56
Fatal bleeding 0.1 0.1 0.84 (0.26-2.75) 0.77
Intracranial bleeding 0.4 0.3 1.09 (0.50-2.39) 0.83
Efficacy (stroke prevention): Eliquis superior to Aspirin
![Page 62: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/62.jpg)
Apixaban – AVERROES
Connolly S, et al. http://www.escardio.org/congresses/esc-2010/congress-reports/Pages/708-3-AVERROES.aspx. Accessed Sept 2010.
Outcome Apixaban (n = 2809)
Aspirin (n = 2791)
Relative Risk (95% CI) P value
Stroke or systemic embolic event 1.6 3.6 0.46 (0.33-0.64) < 0.001
Stroke, embolic event, MI, or vascular death
4.1 6.2 0.66 (0.53-0.83) < 0.001
Major bleeding 1.4 1.2 1.14 (0.74-1.75) 0.56
Fatal bleeding 0.1 0.1 0.84 (0.26-2.75) 0.77
Intracranial bleeding 0.4 0.3 1.09 (0.50-2.39) 0.83
Safety (bleeding): Eliquis similar to Aspirin
![Page 63: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/63.jpg)
Warfarin (target INR 2-3)
Apixaban 5 mg oral twice daily (2.5 mg BID in selected patients)
Primary outcome: stroke or systemic embolism
Hierarchical testing: non-inferiority for primary outcome, superiority for primary outcome, major bleeding, death
Randomize double blind,
double dummy (n = 18,201)
Inclusion risk factors Age ≥ 75 years Prior stroke, TIA, or SE HF or LVEF ≤ 40% Diabetes mellitus Hypertension
Warfarin/warfarin placebo adjusted by INR/sham INR based on encrypted point-of-care testing device
Major exclusion criteria Mechanical prosthetic valve Severe renal insufficiency Need for aspirin plus
thienopyridine
ARISTOTLE Atrial Fibrillation with at Least One Additional Risk Factor for Stroke
Granger et al, NEJM 2011;365:981-92.
![Page 64: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/64.jpg)
ARISTOTLE: Primary Outcome Stroke (ischemic or hemorrhagic) or systemic embolism
Apixaban 212 patients, 1.27% per year Warfarin 265 patients, 1.60% per year HR 0.79 (95% CI, 0.66–0.95); P (superiority)=0.011
No. at Risk Apixaban 9120 8726 8440 6051 3464 1754 Warfarin 9081 8620 8301 5972 3405 1768
P (non-inferiority)<0.001 21% RRR
Granger et al, NEJM 2011;365:981-92.
![Page 65: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/65.jpg)
ARISTOTLE: Major Bleeding (ISTH definition)
Apixaban 327 patients, 2.13% per year Warfarin 462 patients, 3.09% per year HR 0.69 (95% CI, 0.60–0.80); P<0.001
No. at Risk Apixaban 9088 8103 7564 5365 3048 1515 Warfarin 9052 7910 7335 5196 2956 1491
31% RRR
Granger et al, NEJM 2011;365:981-92.
![Page 66: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/66.jpg)
Meta-Analysis: DOACs vs. Warfarin
Stroke or Systemic Embolism
Major Bleeding
Ruff et al, Lancet 2014;383:955-62
Dabig. Rivarox. Apix. Edox.
Dabig. Rivarox. Apix. Edox.
![Page 67: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/67.jpg)
DOACs vs Warfarin and All Cause Mortality
Drug Dose Hazard Ratio (all cause death)
P value (vs. warfarin)
Dabigatran* High Dose (150 mg bid)
0.88 0.051
Low Dose* (110 mg bid)
0.91 0.13
Rivaroxaban 20 or 15 mg daily 0.92 0.15
Apixaban 5 or 2.5 mg bid 0.89 0.047
Edoxaban High Dose (60 or 30 mg daily)
0.92 0.08
Low Dose (30 or 15 mg daily)
0.87 0.006
*Dabigatran 110 mg is not an FDA approved dose for stroke prevention in AF
![Page 68: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/68.jpg)
Idarucizumab (Praxbind) for reversal of dabigatran in patients with bleeding/urgent surgery on dabigatran
Pollack et al, NEJM 2015;373:511-20.
Dose: 5gm IV x1 FDA Approved: 10/16/2015
![Page 69: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/69.jpg)
ANNEXA-4: Andexanet Alfa for reversal of Rivaroxaban and Apixaban in patients with bleeding within 18 hours of DOAC
Connolly SJ et al. N Engl J Med 2016;375:1131-1141
Dose: Bolus + 2 hour infusion for patients with bleeding within 18 hours of DOAC FDA Approved: May 4, 2018
Rivaroxaban Reversal Apixaban Reversal
![Page 70: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/70.jpg)
DOAC Reversal Agent in Development
• Ciraparantag* (PER977):
– (small molecule, binds to anticoagulants) – Reversal agent for Direct Thrombin Inhibitors, Factor Xa inhibitors and
LMWH
*Investigational agent, not FDA approved for clinical use
![Page 71: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/71.jpg)
Clinical Challenges With New Anticoagulants
• No validated tests to measure anticoagulation effect • No established therapeutic range • Antidotes in various stages of development • Assessment of compliance more difficult than with
vitamin K antagonists • Potential for unknown long-term adverse events • Balancing cost against efficacy • Lack of head-to-head studies comparing new agents • Paucity of data on special populations (ESRD, prior
major bleeds, extreme elderly, etc)
![Page 72: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/72.jpg)
Cost Effectiveness of DOACs vs Warfarin for AF
• Large meta-analysis of 23 trials, over 94,000 patients
• On balance, DOACs were more effective at stroke prevention vs. warfarin
• DOACs had lower intracranial bleeding than warfarin
• DOACs were generally cost effective vs. warfarin (accounting for all health care costs)
Lopez-Lopez et al, BMJ 2017;359:j5058
![Page 73: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/73.jpg)
Mechanical Approaches to Stroke Prevention:
LAA Occlusion and Ligation
![Page 74: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/74.jpg)
Left Atrial Appendage (LAA) Closure vs Warfarin for Prevention of Stroke in Patients with AF
Reddy et al, Heart Rhythm Society Late Breaking Trials 2013
Control: warfarin INR 2.0-3.0 Intervention: percutaneous closure of LAA
4 Year Efficacy Composite endpoint of stroke, cardiovascular death, and systemic embolism
• LAA Closure: 2.3%/year • Warfarin: 3.8%/year
4 Year All Cause Mortality • LAA Closure: 3.2%/year • Warfarin: 4.8%/year • Hazard Ratio 0.66, p=0.04
![Page 75: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/75.jpg)
Other LAA Occlusion Devices
Singh et al, Heart Rhythm 2010;7:370-6.
Lariat (LAA Snare)
Amulet Device (*Investigational in US)
![Page 76: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/76.jpg)
Surgical ligation of the left atrial appendage
Superior RAO
Cardiac CT reveals the appendage communicates with the body of the LA via a narrow aperture.
![Page 77: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/77.jpg)
Conclusions
• Rate control is non-inferior to rhythm control for asymptomatic patients
• Strict rate control does not have clear benefit over lenient control
• Antiarrhythmic drugs have moderate efficacy for AF with risks/side effects
• Catheter ablation is more effective than drug therapy for maintenance of sinus rhythm
• Surgical ablation appears to be more effective and more risky than catheter ablation
• Anticoagulation with warfarin is useful for stroke prevention in AF
• New anticoagulants have an expanding role in stroke prevention, but unresolved issues remain
• Left atrial appendage occlusion may offer a future alternative to drug therapy for stroke prevention
![Page 78: Heart Center Template - BLANK TITLEgims19course.com/uploads/1/2/4/0/124037936/2mon-a... · Catheter Ablation vs. Antiarrhythmic Drug Therapy for Paroxysmal AF *Protocol-Defined Treatment](https://reader033.vdocument.in/reader033/viewer/2022052923/5f03f1d67e708231d40b8b70/html5/thumbnails/78.jpg)
Questions?